Organic Active Ingredients TRIZ Cases

Novel pyridone compounds enhance metabolic stability and binding affinity to the c-Met enzyme through targeted structural modifications.

Aqueous thixotropic spray uses microcrystalline cellulose to coat mucosal membranes with high shear viscosity.

Spiro aryl isoxazoline derivatives inhibit 5-lipoxygenase to reduce chronic airway inflammation.

Polyurethane additives prevent phenyl acetone formation, maintaining amphetamine stability in transdermal patches.

Imidazo[1,2-a]pyrazine compounds inhibit the CK2 enzyme to overcome drug resistance in cancer cells.

RNA interference agents silence alpha-mannosidase 2 and Cadherin87A genes, reducing viral load and blocking dengue transmission.

Optimized TLR8 agonists enhance immune responses in neonates and elderly subjects by balancing efficacy with safety profiles.

Administering pridopidine as a Sigma-1 receptor agonist enhances BDNF secretion, addressing inadequate neuroprotective modulation in current treatments.

Formula I compounds modulate KRAS activity to overcome challenges targeting mutant proteins in cancer therapy.

Administering PIP2-stabilizing compounds restores cerebral blood flow and functional hyperemia in CADASIL by modulating Kir2.1 channels.

Administering L-methylfolate treats optic disorders by bypassing enzymatic conversion bottlenecks in patients with folate cycle malfunctions.

A nucleic acid construct uses guide RNA to bind target RNAs and an RNA-cleaving Cas protein to reduce expression in targeted cells.

Replacing calcium salts with bivalent metal oxides increases phosphatidylserine yield to 90% while lowering production costs.

Core-to-surface polymerization reduces ruthenium catalyst impurities below 450 ppm while enabling pharmaceutical agent incorporation.

Modified imidazole structures deliver anesthesia while preserving adrenocortical hormone synthesis, resolving the trade-off between efficacy and adrenal safety.

Granular pantoprazole particles enable direct compression, eliminating heat-induced degradation during drying.

S1P and ATX modulating agents target specific molecular pathways to promote myelination.

Immobilization particles use spacer structures to bind pathogens, preserving microbiome balance and preventing autoimmune reactions.

Nasal DIMEB delivery bypasses the blood-brain barrier via olfactory nerves, avoiding pulmonary toxicity from systemic dosing while inhibiting prion aggregation.

An injectable ethyl cellulose gel depot prevents drug leakage from tumor cracks while enabling image-guided photodynamic therapy.

Cis-configured morpholine derivatives resolve metabolic stability issues in somatostatin receptor 4 agonists, achieving high potency and brain penetration.

Flash-freezing cannabinoid mixtures with liquid nitrogen creates spreadable pastes that mitigate cholesterol risks from traditional butter production.

Cationic carrier units form micelles to shield polynucleotides from nuclease degradation while enabling transmembrane transport.

Combining EGFR, MEK, and CDK inhibitors treats BRAF mutation cancers without BRAF inhibitors.

Orally disintegrating baclofen composition overcomes poor absorption by utilizing crospovidone and F-MELT excipients to achieve rapid breakdown.

CAR-T cells targeting CT45 overcome chemotherapy resistance in aggressive ovarian cancer.

Fermentation alcohol precipitates ginseng polysaccharides, isolating specific sugar compositions that enhance immune function.

CHRNB3 inhibitors reduce smoking frequency by targeting genetic variants to address underlying addiction mechanisms.

AIM protein addresses non-alcoholic steatohepatitis pathology using high-fat diet knockout mice to replicate human metabolic syndrome conditions.

Replacing water with ethanol and polyethoxylated derivatives enables high-concentration melatonin solubility without degradation or precipitation.

A biodegradable dextran matrix releases polysaccharide to inhibit cell migration and prevent post-surgical adhesion formation.

Antibodies neutralize sclerostin to stimulate bone formation, overcoming limited efficacy of resorption inhibitors.

Combining eIF5A and Notch inhibitors enriches regulatory T cells to protect pancreatic beta cells from immune destruction in Type 1 diabetes.

Guanidine hydrochloride disrupts hydrogen bonds to block macromolecule uptake, inhibiting rapid cancer cell proliferation.

S-substituted amino mercaptopropionate derivatives release hydrogen sulfide to provide neuroprotective effects.

Benzofuran bicyclic benzamide compounds target the HCV NS5B enzyme, resolving toxicity issues found in prior therapies.

Formula I compounds inhibit non-phagytic NADPH oxidase isoforms to lower ROS levels while preserving immune cell function.

Guanidinium macromolecules with monosaccharide targeting moieties selectively kill multidrug-resistant bacteria while minimizing mammalian cell toxicity.

Low-temperature deposition of viscous filling into a setting gelatinous shell prevents active ingredient decomposition and leakage without foam layers.

Novel FXR agonist compounds modulate farnesoid X receptor activity, addressing insufficient therapeutic outcomes in existing treatments.

Pharmacological formulation strengthens ciliary muscle contraction to enhance accommodation and increase depth of focus.

Inhalation bypasses gastrointestinal absorption variability to stabilize plasma levels and reduce motor fluctuations in Parkinson's disease.

Gamma-amino alcohol derivatives block transporter proteins to prevent rapid reuptake, maintaining optimal signaling precision and reducing side effects.

A SN-38 poly(amino acid) block copolymer formulation enhances aqueous solubility for cancer therapy.